Stereotactic radiotherapy (SRT) for differentiated thyroid cancer (DTC) oligometastases: an AIRO (Italian association of radiotherapy and clinical oncology) systematic review.
Differentiated thyroid cancer
Oligometastases
Outcomes
Stereotactic radiotherapy
Toxicity
Journal
La Radiologia medica
ISSN: 1826-6983
Titre abrégé: Radiol Med
Pays: Italy
ID NLM: 0177625
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
04
12
2021
accepted:
23
03
2022
pubmed:
9
4
2022
medline:
27
5
2022
entrez:
8
4
2022
Statut:
ppublish
Résumé
The aim of this systematic review was to examine efficacy of stereotactic radiotherapy (SRT) in patients with oligometastatic thyroid cancer. A systematic search was conducted by means of PubMed, Scopus, and Cochrane library. gov was searched for ongoing or recently completed trials, and PROSPERO was searched for ongoing or recently completed systematic reviews. We analyzed only clinical studies as full text carried out on patients with oligometastatic thyroid cancer treated with SRT. Conference papers, surveys, letters, editorials, book chapters, and reviews were excluded. Time of publication was restricted to the years 1990-2021. The number of evaluated patients was 146 (267 lesions), and the median age was 58 years. The median 1-year local control (LC) was 82% (range 67.0%-97.1%); the median disease-free survival (DFS) was 12 months (range 4-53); the median 1-year overall survival was 72% (range 66.6%-85.0%); the 3-year cancer-specific survival was 75.0%; and the 4-year cancer-specific survival was 37.5%. No grade 3-5 acute toxicity was reported. No late effects were recorded. SRT for oligometastases from thyroid cancer as salvage therapy is well tolerated and yields high rates of LC and prolonged DFS.
Identifiants
pubmed: 35394605
doi: 10.1007/s11547-022-01489-2
pii: 10.1007/s11547-022-01489-2
doi:
Types de publication
Journal Article
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
681-689Subventions
Organisme : 5x1000 per la Ricerca Sanitaria
ID : no grant number provided
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : 21879
Organisme : Italian Ministry of Health (Ricerca Corrente)
ID : RCR-2020-23670066
Informations de copyright
© 2022. Italian Society of Medical Radiology.
Références
I numeri del cancro in Italia 2021 (2021), Intermedia editore.
Schlumberger M, Challeton C, De Vathaire F, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605
pubmed: 8691248
Mihailovic J, Stefanovic L, Malesevic M (2007) Differentiated thyroid carcinoma with distant metastases: probability of survival and its predicting factors. Cancer Biother Radiopharm 22(2):250–255. https://doi.org/10.1089/cbr.2006.313
doi: 10.1089/cbr.2006.313
pubmed: 17600472
Sugitani I, Fujimoto Y, Yamamoto N (2008) Papillary thyroid carcinoma with distant metastases: survival predictors and the importance of local control. Surgery 143:35–42. https://doi.org/10.1016/j.surg.2007.06.011
doi: 10.1016/j.surg.2007.06.011
pubmed: 18154931
Shaha AR, Shah JP, Loree TR (1997) Differentiated thyroid cancer presenting initially with distant metastasis. Am J Surg 174:474–476. https://doi.org/10.1016/s0002-9610(97)00158-x
doi: 10.1016/s0002-9610(97)00158-x
pubmed: 9374217
Showalter TN, Siegel BA, Moley JF, Baranski TJ, Grigsby PW (2008) Prognostic factors in patients with well-differentiated thyroid cancer presenting with pulmonary metastasis. Cancer Biother Radiopharm 23:655–659. https://doi.org/10.1089/cbr.2008.0501
doi: 10.1089/cbr.2008.0501
pubmed: 18976119
Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Nat Thyroid Cancer Treatment Cooper Study Registry Group Cancer 83:1012–1021. https://doi.org/10.1002/(sici)1097-0142(19980901)83:5%3c1012::aid-cncr28%3e3.0.co;2-9
doi: 10.1002/(sici)1097-0142(19980901)83:5<1012::aid-cncr28>3.0.co;2-9
Sampson E, Brierley JD, Le LW, Rotstein L, Tsang RW (2007) Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 110:1451–1456. https://doi.org/10.1002/cncr.22956
doi: 10.1002/cncr.22956
pubmed: 17705176
Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892–2899. https://doi.org/10.1210/jc.2005-2838
doi: 10.1210/jc.2005-2838
pubmed: 16684830
Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM (2006) Real-time prognosis for metastatic thyroid carcinoma based on 2-(18F)fluoro-2-deoxy-D-glucose-positron emission tomography scanning. JCEM 91:498–505. https://doi.org/10.1210/jc.2005-1534
doi: 10.1210/jc.2005-1534
pubmed: 16303836
Ringel MD (2011) Metastatic dormancy and progression in thyroid cancer: targeting cells in the metastatic frontier. Thyroid 21:487–492. https://doi.org/10.1089/thy.2011.2121
doi: 10.1089/thy.2011.2121
pubmed: 21476892
pmcid: 3092721
Muresan MM, Olivier P, Leclere J, Leclère J, Sirveaux F, Brunaud L, Klein M, Zarnegar R (2008) Weryha G (2008) Bone metastases from differentiated thyroid carcinoma. Endocr Relat Cancer 15:37–49. https://doi.org/10.1677/ERC-07-0229
doi: 10.1677/ERC-07-0229
pubmed: 18310274
Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ (2000) Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. Thyroid 10:261–268. https://doi.org/10.1089/thy.2000.10.261
doi: 10.1089/thy.2000.10.261
pubmed: 10779141
Wu K, Hou SM, Huang TS, Yang RS (2008) Thyroid carcinoma with bone metastases: a prognostic factor study. Clin Med Oncol 2:129–134. https://doi.org/10.4137/cmo.s333
doi: 10.4137/cmo.s333
pubmed: 21892275
pmcid: 3161655
Farooki A, Leung V, Tala H, Tuttle RM (2012) Skeletal related events due to bone metastases from differentiated thyroid cancer. J Clin Endocrinol Metab 97:2433–2439. https://doi.org/10.1210/jc.2012-1169
doi: 10.1210/jc.2012-1169
pubmed: 22564664
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1–133. https://doi.org/10.1089/thy.2015.0020
doi: 10.1089/thy.2015.0020
pubmed: 26462967
pmcid: 4739132
Perros P, Boelaert K, Colley S, Evans C, Evans RM, Gerrard Ba G, Gilbert J, Harrison B, Johnson SJ, Giles TE, Moss L, Lewington V, Newbold K, Taylor J, Thakker RV, Watkinson J, Williams GR (2014) British Thyroid Association. Guidelines Manag Thyroid Cancer 81:1–122. https://doi.org/10.1111/cen.12515
doi: 10.1111/cen.12515
Kocher M, Soffietti R, Abacioglu U, Villà S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, Ben Hassel M, Kouri M, Valeinis E, van den Berge D, Collette S, Collette L, Mueller RP (2011) Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952–26001 study. J Clin Oncol 29:134–141. https://doi.org/10.1200/JCO.2010.30.1655
doi: 10.1200/JCO.2010.30.1655
pubmed: 21041710
Chang EL, Shiu AS, Mendel E, Mathews LA, Mahajan A, Allen PK, Weinberg JS, Brown BW, Wang XS, Woo SY, Cleeland C, Maor MH, Rhines LD (2007) Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failure. J Neurosurg Spine 7:151–160
doi: 10.3171/SPI-07/08/151
Chang EL, Shiu AS, Lii MF, Rhines LD, Mendel E, Mahajan A, Weinberg JS, Mathews LA, Brown BW, Maor MH, Cox JD (2004) Phase I clinical evaluation of near simultaneous computed tomographic image-guided stereotactic body radiotherapy for spinal metastases. Int J Radiat Oncol Biol Phys 59:1288–1294. https://doi.org/10.3171/SPI-07/08/151
doi: 10.3171/SPI-07/08/151
pubmed: 15275711
Folkert MR, Bilsky MH, Tom AK, Oh JH, Alektiar KM, Laufer I, Tap WD, Yamada Y (2014) Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. Int J Radiat Oncol Biol Phys 88:1085–1091. https://doi.org/10.1016/j.ijrobp.2013.12.042
doi: 10.1016/j.ijrobp.2013.12.042
pubmed: 24661662
Hall WA, Stapleford LJ, Hadjipanayis CG, Curran WJ, Crocker I, Shu HKG (2011) Stereotactic body radiosurgery for spinal metastatic disease: an evidence-based review. Int J Surg Oncol 2011:979214. https://doi.org/10.1155/2011/979214
doi: 10.1155/2011/979214
pubmed: 22312536
pmcid: 3263656
Bishop AJ, Tao R, Rebueno NC, Christensen EN, Allen PK, Wang XA, Amini B, Tannir NM, Tatsui CE, Rhines LD, Li J, Chang EL, Brown PD, Ghia AJ (2015) Outcomes for spine stereotactic body radiation therapy and an analysis of predictors of local recurrence. Int J Radiat Oncol Biol Phys 92:1016–1026. https://doi.org/10.1016/j.ijrobp.2015.03.037
doi: 10.1016/j.ijrobp.2015.03.037
pubmed: 26025777
Lovelock DM, Zhang Z, Jackson A, Keam J, Bekelman J, Bilsky M, Lis E, Yamada Y (2010) Correlation of local failure with measures of dose insufficiency in the high-dose single-fraction treatment of bony metastases. Int J Radiat Oncol Biol Phys 77:1282–1287. https://doi.org/10.1016/j.ijrobp.2009.10.003
doi: 10.1016/j.ijrobp.2009.10.003
pubmed: 20350795
pmcid: 3319455
Gill B, Oermann E, Ju A, Suy S, Yu X, Rabin J, Kalhorn C, Nair MN, Voyadzis JM, Unger K, Collins SP, Harter KW, Collins BT (2012) Fiducial-free CyberKnife stereotactic body radiation therapy (SBRT) for single vertebral body metastases: acceptable local control and normal tissue tolerance with 5 fraction approach. Front Oncol 2:39. https://doi.org/10.3389/fonc.2012.00039
doi: 10.3389/fonc.2012.00039
pubmed: 22645718
pmcid: 3355827
Hariri O, Takayanagi A, Lischalk J, Desai K, Florence TJ, Yazdian P, Chang SD, Vrionis F, Adler JR, Quadri SA, Desai A (2019) Clinical efficacy of frameless stereotactic radiosurgery in the management of spinal metastases from thyroid carcinoma. Spine (Phila Pa 1976) 44: 1188–95. https://doi.org/10.1097/BRS.0000000000003087 .
Ishigaki T, Uruno T, Sugino K, Masaki C, Akaishi J, Hames KY, Suzuki A, Tomoda C, Matsuzu K, Ohkuwa K, Kitagawa W, Nagahama M, Miyazaki S, Ito K (2019) Stereotactic radiotherapy using the CyberKnife is effective for local control of bone metastases from differentiated thyroid cancer. J Radiat Res 60:831–836. https://doi.org/10.1093/jrr/rrz056
doi: 10.1093/jrr/rrz056
pubmed: 31423531
pmcid: 6873619
Bernstein MB, Chang EL, Amini B, Pan H, Cabanillas M, Wang XA, Allen PK, Rhines LD, Tatsui C, Li J, Brown PD, Ghia AJ (2016) Spine stereotactic radiosurgery for patients with metastatic thyroid cancer: secondary analysis of Phase I/II trials. Thyroid 26:1269–1275. https://doi.org/10.1089/thy.2016.0046
doi: 10.1089/thy.2016.0046
pubmed: 27334245
Bernad DM, Sperduto PW, Souhami L, Jensen AW, Roberge D (2010) Stereotactic radiosurgery in the management of brain metastases from primary thyroid cancers. J Neurooncol 98:249–252. https://doi.org/10.1007/s11060-010-0175-z
doi: 10.1007/s11060-010-0175-z
pubmed: 20376550
Kim I-Y, Kondziolka D, Niranjan A, Flickinger JC, Lunsford LD (2009) Gamma knife radiosurgery for metastatic brain tumors from thyroid cancer. J Neurooncol 93:355–359. https://doi.org/10.1007/s11060-008-9783-2
doi: 10.1007/s11060-008-9783-2
pubmed: 19139821
McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC (2003) Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. Cancer 98:356–362. https://doi.org/10.1002/cncr.11488
doi: 10.1002/cncr.11488
pubmed: 12872357
Bunevicius A, Fribance S, Pikis S, Lee JYK, Buch LY, Moran M, Yang AI, Bernstein K, Mathieu D, Perron R, Liscak R, Simonova G, Patel S, Trifiletti DM, Martínez Álvarez R, Martínez Moreno N, Lee CC, Yang HC, Strickland BA, Zada G, Chang EL, Kondziolka D, Sheehan J (2021) Stereotactic radiosurgery for differentiated thyroid cancer brain metastases: an international, multicenter study. Thyroid 31:1244–1252. https://doi.org/10.1089/thy.2020.0947
doi: 10.1089/thy.2020.0947
pubmed: 33978475
Gomes-Lima CJ, Wu D, Rao SN, Punukollu S, Hritani R, Zeymo A, Deeb H, Mete M, Aulisi EF, Van Nostrand D, Jonklaas J, Wartofsky L, Burman KD (2018) Brain metastases from differentiated thyroid carcinoma: prevalence, current therapies, and outcomes. J Endocr Soc 3:359–371. https://doi.org/10.1210/js.2018-00241
doi: 10.1210/js.2018-00241
pubmed: 30706042
pmcid: 6348752
Gerszten PC, Burton SA, Ozhasoglu C, Welch WC (2007) Radiosurgery for spinal metastases: clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976) 32:193–199. https://doi.org/10.1097/01.brs.0000251863.76595.a2
doi: 10.1097/01.brs.0000251863.76595.a2
Tahara M (2018) Management of recurrent or metastatic thyroid cancer. ESMO Open. 3(Suppl 1):000359
Yamada Y, Katsoulakis E, Laufer I, Lovelock M, Barzilai O, McLaughlin LA, Zhang Z, Schmitt AM, Higginson DS, Lis E, Zelefsky MJ, Mechalakos J, Bilsky MH (2017) The impact of histology and delivered dose on local control of spinal metastases treated with stereotactic radiosurgery. Neurosurg Focus 42:E6. https://doi.org/10.3171/2016.9.FOCUS16369
doi: 10.3171/2016.9.FOCUS16369
pubmed: 28041329
pmcid: 5568686
Chang UK, Cho WI, Kim MS, Cho CK, Lee DH, Rhee CH (2012) Local tumor control after retreatment of spinal metastasis using stereotactic body radiotherapy; comparison with initial treatment group. Acta Oncol 51:589–595. https://doi.org/10.3109/0284186X.2012.666637
doi: 10.3109/0284186X.2012.666637
pubmed: 22414095
Chen H, Louie AV, Boldt RG, Rodrigues GB, Palma DA, Senan S (2016) Quality of life after stereotactic ablative radiotherapy for early-stage lung cancer: a systematic review. Clin Lung Cancer 17:141–149. https://doi.org/10.1016/j.cllc.2015.12.009
doi: 10.1016/j.cllc.2015.12.009
Ryu S, Jin JY, Jin R, Rock J, Ajlouni M, Movsas B, Rosenblum M (2007) Kim JH (2007) Partial volume tolerance of the spinal cord and complications of single-dose radiosurgery. Cancer 109:628–636. https://doi.org/10.1002/cncr.22442
doi: 10.1002/cncr.22442
pubmed: 17167762
Huo M, Sahgal A, Pryor D, Redmond K, Lo S, Foote M (2017) Stereotactic spine radiosurgery: review of safety and efficacy with respect to dose and fractionation. Surg Neurol Int 8:30. https://doi.org/10.4103/2152-7806.200581
doi: 10.4103/2152-7806.200581
pubmed: 28303210
pmcid: 5339918
Katsoulakis E, Jackson A, Cox B, Lovelock M, Yamada Y (2017) A detailed dosimetric analysis of spinal cord tolerance in high-dose spine radiosurgery. Int J Radiat Oncol Biol Phys 99:598–607. https://doi.org/10.1016/j.ijrobp.2017.05.053
doi: 10.1016/j.ijrobp.2017.05.053
pubmed: 29280455
Rose PS, Laufer I, Boland PJ, Hanover A, Bilsky MH, Yamada J, Lis E (2009) Risk of fracture after single fraction image-guided intensity-modulated radiation therapy to spinal metastases. J Clin Oncol 27:5075–5079. https://doi.org/10.1200/JCO.2008.19.3508
doi: 10.1200/JCO.2008.19.3508
pubmed: 19738130
pmcid: 3664037
Boehling NS, Grosshans DR, Allen PK, McAleer MF, Burton AW, Azeem S, Rhines LD, Chang EL (2012) Vertebral compression fracture risk after stereotactic body radiotherapy for spinal metastases. J Neurosurg Spine 16:379–386. https://doi.org/10.3171/2011.11.SPINE116
doi: 10.3171/2011.11.SPINE116
pubmed: 22225488
Faruqi S, Tseng C-L, Whyne C, Alghamdi M, Wilson J, Myrehaug S, Soliman H, Lee Y, Maralani P, Yang V, Fisher C, Sahgal A (2018) Vertebral compression fracture after spine stereotactic body radiation therapy: a review of the pathophysiology and risk factors. Neurosurgery 83:314–322. https://doi.org/10.1093/neuros/nyx493
doi: 10.1093/neuros/nyx493
pubmed: 29048517
Heron DE, Rajagopalan MS, Stone B, Burton S, Gerszten PC, Dong X, Gagnon GJ, Quinn A, Henderson F (2012) Single-session and multisession CyberKnife radiosurgery for spine metastases-University of Pittsburgh and Georgetown University experience. J Neurosurg Spine 17:11–18. https://doi.org/10.3171/2012.4.SPINE11902
doi: 10.3171/2012.4.SPINE11902
pubmed: 22578235
Bãrbuş E, Peştean C, Larg MI, Piciu D (2017) Quality of life in thyroid cancer patients: a literature review. Clujul Med 90:147–153. https://doi.org/10.15386/cjmed-703
doi: 10.15386/cjmed-703
pubmed: 28559697
pmcid: 5433565
Xing M, Haugen BR, Schlumberger M (2013) Progress in molecular-based management of differentiated thyroid cancer. Lancet 381:1058–1069. https://doi.org/10.1016/S0140-6736(13)60109-9
doi: 10.1016/S0140-6736(13)60109-9
pubmed: 23668556
pmcid: 3931461
Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK, Sherman SI, Smit JW, Chung J, Kappeler C, Peña C, Molnár I, Schlumberger MJ, DECISION investigators (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384:319–328. https://doi.org/10.1016/S0140-6736(14)60421-9
doi: 10.1016/S0140-6736(14)60421-9
pubmed: 24768112
pmcid: 4366116
Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621–630. https://doi.org/10.1056/NEJMoa1406470
doi: 10.1056/NEJMoa1406470
pubmed: 25671254
Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR, Read J, Langmuir P, Ryan AJ, Schlumberger MJ (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134–141. https://doi.org/10.1200/JCO.2011.35.5040
doi: 10.1200/JCO.2011.35.5040
pubmed: 22025146
Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC, Niederle B, Cohen EE, Wirth LJ, Ali H, Hessel C, Yaron Y, Ball D, Nelkin B, Sherman SI (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639–3646. https://doi.org/10.1200/JCO.2012.48.4659
doi: 10.1200/JCO.2012.48.4659
pubmed: 24002501
pmcid: 4164813
Tagliaferri L, Gobitti C, Colloca GF, Boldrini L, Farina E, Furlan C, Paiar F, Vianello F, Basso M, Cerizza L, Monari F, Simontacchi G, Gambacorta MA, Lenkowicz J, Dinapoli N, Lanzotti V, Mazzarotto R, Russi E, Mangoni M (2018) A new standardized data collection system for interdisciplinary thyroid cancer management: thyroid COBRA. Eur J Intern Med 53:73–78. https://doi.org/10.1016/j.ejim.2018.02.012
doi: 10.1016/j.ejim.2018.02.012
pubmed: 29477755